Peter Lüdike

Cardiology & Vascular Medicine, Heart Failure & Intensive Care, MCS , TMTT 🚴‍♂️

[I.H.Tanboga, MD, PhD @ihtanboga]

https://t.co/TCrXVVCF8K

[Peter Lüdike @luedike]

@drjohnm https://t.co/6OWJ83Kdo8

[Anish Koka, MD @anish_koka]

https://t.co/pDqo6cETxT

[Johann Bauersachs @JBauersachsMD]

#DIGIT_HF will change clinical practice for patients with #HFrEF ‼️

⁦@ShelleyZieroth⁩ ⁦@DavidDuncker⁩ ⁦@escardio⁩ #ESCCongress2025 ⁦@YoungDgk⁩ ⁦@DGK_org⁩ ⁦@NEJM⁩

[Peter Lüdike @luedike]

@DocRoccoBene @ZoiNetou @kardiolancerin @Medibubble @notfallguru 😂😂

[Johann Bauersachs @JBauersachsMD]

#DGKHerztage nicht verpassen am Freitag 9.45 ✅
➡️ #HIGHLIGHT Session mit
3️⃣ #Herzinsuffizienz Studien‼️

@realdocdan @DjawidHashemi @papathanasiou_ @Kardiophil @Hannah_Billig_ @DavidDuncker @DGK_org @YoungDgk @AGEP_DGK @SamiraSoltaniMD @TRassafMD @luedike @MHH_life

[Daniel Messiha, MD @realdocdan]

#HFpEF mit ⬆️ Prävalenz & schlechter Prognose
👉 frühzeitig an kardiale Amyloidose denken
👉 besonderer Wert der MR-Antagonisten & SGLT2i bei kardialer Amyloidose aufgrund guter Toleranz
👉 Anbindung an Zentrum

#DGKHerztage #Herzinsuffizienz @DGK_org @YoungDgk @Herzmedizin_de

[Nicole Karam, MD, PhD, FESC @nickaram]

mTEER is non inferior to Surgery in #SMR patients with respect to a composite of death, rehospitalization for heart failure, stroke, reintervention, or implantation of an assist device at 1 year. MATTERHORN trail #ESCCongress2024 @PCRonline
https://t.co/Nt9OYp25VK

[Nicole Karam, MD, PhD, FESC @nickaram]

Excellent results with #TEER + OMT vs OMT in patients with severe SMR. The end of a debate? #ESCCongress2024 @PCRonline

[RTHahnMD @hahn_rt]

RESHAPE-HF2 shows no impact on mortality but significant reduction in HFH and improvement in KCCQ. All call for a larger trial to confirm MTEER for lower risk and lower MR severity. #ESC2024

[Ronald Witteles @Ron_Witteles]

🚨🚨🚨 MAJOR news in the #amyloidosis world this morning with positive topline results of #HELIOS-B. #Vutrisiran met all primary & secondary endpoints. Let's break down what we know... #StanfordAmyloidCenter (1/13)

[Patrick Sullivan @PSullivan000]

Tailoring PEEP through real-time RV #PVLoop #Hemodynamics in VA-ECMO patients

"This unique approach of tailoring mech ventilation via cardio-respiratory physiology through in-vivo RV #PVloops may provide a novel way to optimize patient outcomes."

Link: https://t.co/0GbOoJIOmG

[Yogesh Reddy @yreddyhf]

Why do HF patients often have low BP and orthostasis? And what does it mean for clinical practice? See great new study in @JCardFail and editorial for context below.

https://t.co/LJIGaFZofy

[Peter Lüdike @luedike]

💥🔥off-the-press!!! CONGRATULATIONS @MGercek40 & @VolkerRudolph1 on this important and sophisticated Study!!! It was a pleasure&honor to support this 🤝!!! #TEER @YoungDgk @DGK_org @AGIKinterv

[Andrew J Sauer MD @AndrewJSauer]

Patients will soon be able to bring their phone into your office and say,

"Hey doctor, my phone says I have heart failure...what does this mean?"

More technology disrupting the status quo in identifying, diagnosing, and treating patients with heart failure.

Lets go.

Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors | JACC: Heart Failure

[Polizei Mannheim @PolizeiMannheim]

Wir trauern um unseren Kollegen – um andere zu schützen hat er sein Leben gegeben!

Am Freitag wurde unser Kollege vom PP Mannheim durch einen Messerangriff schwer verletzt und ist heute seinen Verletzungen erlegen.

PM des LKA: https://t.co/Bf1VqoSxro

#einervonuns
#mannheim

[JACC Journals @JACCJournals]

ICYMI: #EchoFirst outcomes from #MTEER #CLASPIID randomized trial for degenerative #vhdMR: #PASCAL system use & smaller flail gaps ➡️ more likely to have mild or less MR at 6 months. https://t.co/8qBy2fFpfz

#JACCIMG @hahn_rt @DanielKalbacher @TobiasFRuf @SasanRaissi

[JACC Journals @JACCJournals]

Secondary analysis of the PRE18FFIR study showed individual coronary atherosclerotic plaque activity is associated with subsequent myocardial infarction in the same coronary artery territory, which cascades into patient-level risk https://t.co/PGUO9NDw4o

#JACC #cvMI #cvPET

[Johann Bauersachs @JBauersachsMD]

🔥hot of the press:
Great Debate: #SGLT2 inhibitors should be first-line treatment in #HFrEF ✅

https://t.co/E14HhOUAs2

@ehj_ed @rudolf_deboer @ShelleyZieroth @DavidDuncker @SamiraSoltaniMD @YoungDgk @MHH_life @GiuseppeGalati_ @Kardiophil @Hannah_Billig_ @realdocdan @TRassafMD